Georgia Panagiotakos, PhD
About Me
Dr. Panagiotakos is an Associate Professor in the Departments of Psychiatry and Neuroscience. She is also a member of the Institute for Regenerative Medicine, the Seaver Autism Center for Research and Treatment, the Mindich Child Health and Development Institute, the Black Family Stem Cell Institute, the Alper Center for Neural Development and Regeneration, and the Friedman Brain Institute. Her laboratory is focused on investigating cellular and molecular mechanisms that regulate brain development, with an eye towards understanding the underpinnings of neurodevelopmental disorders. The Panagiotakos lab has been especially interested in electrical signals in the developing brain and disease-associated ion channels that convert electrical signals into long term biochemical changes as immature neural cells adopt their mature identities in the brain. Learn more about the Panagiotakos lab here.
Language
English
Position
ASSOCIATE PROFESSOR | Graduate Education, ASSOCIATE PROFESSOR | Psychiatry, ASSOCIATE PROFESSOR | Neuroscience, ASSOCIATE PROFESSOR | Stem Cell Biology And Regenerative Medicine
Research Topics
Autism, Cell Biology, Cellular Differentiation, Developmental Neurobiology, Membrane Proteins/Channels, Neuroscience, Psychiatry, RNA Splicing & Processing, Stem Cells
Multi-Disciplinary Training Areas
Development Regeneration and Stem Cells [DRS], Genetics and Genomic Sciences [GGS], Neuroscience [NEU]
Education
PhD, Stanford University School of Medicine
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Panagiotakos did not report having any of the following types of financial relationships with industry and other outside entities during 2025 and/or 2026: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.